文献速递哮喘

巨噬细胞移动抑制因子促进重症哮喘中性粒细胞炎症的糖皮质激素抵抗

Macrophage migration inhibitory factor promotes glucocorticoid resistance of neutrophilic inflammation in a murine model of severe asthma.
PubMed 文献 · Thorax · 2022-11-07

该研究基于U-BIOPRED队列发现痰MIF蛋白与既往一年急性加重次数、痰中性粒细胞及口服糖皮质激素使用正相关,TAC2亚型中MIF升高而annexin-A1降低。小鼠重症哮喘模型中MIF拮抗剂ISO-1可抑制中性粒细胞炎症并提高糖皮质激素反应性,机制涉及MIF直接结合并剪切annexin-A1。

要点

  • 痰MIF蛋白与重症哮喘急性加重次数、痰中性粒细胞及口服激素使用正相关
  • MIF通过剪切annexin-A1降低其生物活性,促进中性粒细胞炎症的激素抵抗
  • MIF拮抗剂ISO-1在小鼠模型中抑制中性粒细胞炎症并改善激素反应性

核心结论

  • MIF通过降低annexin-A1的生物活性促进中性粒细胞炎症的糖皮质激素抵抗,提示MIF是重症中性粒细胞性哮喘的潜在治疗靶点。

研究设计与样本

  • 基于U-BIOPRED队列分析痰MIF蛋白与重症中性粒细胞性哮喘临床及分子特征的相关性。
  • 在重症哮喘小鼠模型中体内研究MIF对中性粒细胞炎症和糖皮质激素反应性的调控。

主要发现

  • U-BIOPRED全部受试者中MIF蛋白水平与既往一年急性加重次数、痰中性粒细胞数及口服糖皮质激素使用正相关。
  • 按U-BIOPRED定义的TAC分析,TAC2中MIF蛋白升高、annexin-A1蛋白相应降低,TAC2与气道中性粒细胞增多及NLRP3炎症小体激活最相关。
  • 小鼠重症哮喘模型中MIF拮抗剂ISO-1显著抑制中性粒细胞炎症并提高糖皮质激素反应性。
  • 肺组织裂解液免疫共沉淀显示MIF直接与annexin-A1相互作用并将其剪切,可能降低其生物活性。

临床怎么用

  • 对重症中性粒细胞性哮喘患者,痰MIF水平可能提示激素抵抗与急性加重风险。
  • MIF拮抗可能作为改善此类患者糖皮质激素反应性的潜在策略。

局限性

  • 机制与干预证据主要来自小鼠模型,人体仅为相关性观察,尚需临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Severe neutrophilic asthma is resistant to treatment with glucocorticoids. The immunomodulatory protein macrophage migration inhibitory factor (MIF) promotes neutrophil recruitment to the lung and antagonises responses to glucocorticoids. We hypothesised that MIF promotes glucocorticoid resistance of neutrophilic inflammation in severe asthma. METHODS: We examined whether sputum MIF protein correlated with clinical and molecular characteristics of severe neutrophilic asthma in the Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) cohort. We also investigated whether MIF regulates neutrophilic inflammation and glucocorticoid responsiveness in a murine model of severe asthma in vivo. RESULTS: MIF protein levels positively correlated with the number of exacerbations in the previous year, sputum neutrophils and oral corticosteroid use across all U-BIOPRED subjects. Further analysis of MIF protein expression according to U-BIOPRED-defined transcriptomic-associated clusters (TACs) revealed increased MIF protein and a corresponding decrease in annexin-A1 protein in TAC2, which is most closely associated with airway neutrophilia and NLRP3 inflammasome activation. In a murine model of severe asthma, treatment with the MIF antagonist ISO-1 significantly inhibited neutrophilic inflammation and increased glucocorticoid responsiveness. Coimmunoprecipitation studies using lung tissue lysates demonstrated that MIF directly interacts with and cleaves annexin-A1, potentially reducing its biological activity. CONCLUSION: Our data suggest that MIF promotes glucocorticoid-resistance of neutrophilic inflammation by reducing the biological activity of annexin-A1, a potent glucocorticoid-regulated protein that inhibits neutrophil accumulation at sites of inflammation. This represents a previously unrecognised role for MIF in the regulation of inflammation and points to MIF as a potential therapeutic target for the management of severe neutrophilic asthma.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Allam VSRR, Pavlidis S, Liu G, et al. Macrophage migration inhibitory factor promotes glucocorticoid resistance of neutrophilic inflammation in a murine model of severe asthma. Thorax. 2022. PMID: 36344253. doi:10.1136/thorax-2021-218555

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。